NTLA INTELLIA Lands Up to $400M Non-Dilutive Debt Facility From OrbiMed The CRISPR company drew $75 million at closing, with $325 million more tied to milestones ahead of a planned U.S. launch of lonvo-z in hereditary angioedema.
